The variant omicron of the Covid-19 has caused the United States to beat its own record of people hospitalized by the virus.
This week the figure of 145,982 has been reached, which means surpassing the above, reached just one year ago.
The big difference is that the omicron variant, although much more contagious, is much less aggressive.
In fact, the number of deceased by the COVID-19 has been ranging between 1,000 and 2,000 daily since September, and it does not seem that the figure is increasing, at least for the time being, despite the increase in cases.
In January 2021, the worst month of the pandemic in the US, 3,136 people were killed up to date on average.
In June, the deaths had descended 342 daily.
In the US it is only vaccinated with two doses of 62.3% and the population susceptible to immunized.
At the current rhythm, that country will not achieve 90% that have already exceeded countries such as Spain until the end of September.
The States controlled by the Republican Party oppose the measures of social isolation, and to the obligation of the use of masks and even vaccines.
While the country is still sinking in its omicron, the CEO of Pfizer, Albert Bourla, has declared that this company is manufacturing a new vaccine against the omicron variant that expects it to be in a position to be distributed in March.
Bourla, who made the announcement in an interview on CNBC Financial Television, implied that the current vaccine is not effective against the transmission of omicron.
“We are working on a new version of the vaccine that is also effective against omicron, it is not that the current vaccine is not effective against the other variants, but [the new vaccine will be effective] against omicron too,” she said.
According to the manager, the current vaccine gives “a reasonable protection against hospitalizations whenever you have the third dose”, and the new version will be effective “especially against infections”.
The manager declared that he does not know “if we will need it or if it will be necessary.”
The other pharmaceutical one that has been more successful in the manufacture and distribution of vaccines against VOCID-19, modern, has initiated clinical trials of its version against omicron.
